CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a market cap of $3.81 billion, a price-to-earnings ratio of -17.33 and a beta of 0.50.

abrdn plc lifted its position in Scholar Rock by 28.2% during the third quarter. abrdn plc now owns 748,489 shares of the company’s stock valued at $5,995,000 after buying an additional 164,715 ...

CAMBRIDGE, Mass., January 17, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

(RTTNews) - Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, Wednesday announced the appointment ...

Lisa Wyman brings more than 20 years of leadership and functional experience to new role of Chief Technical and Quality Officer on the Executive Team at Scholar Rock - Ted Myles, Chief Operating ...

Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

C AMBRIDGE, MA—Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold a portion of her holdings in the company. According to a filing with the ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...